An "abundance of caution" led to last week's product recall by Tylenol maker McNeil Consumer Healthcare, a U.S. Food and Drug Administration spokeswoman said. But drug safety experts said that serious or not, the episode proves that not just generic drugs can fall victim to quality control problems.
"This recall provides compelling evidence that quality assurance is an issue for all drugmakers, and is not specific to generic products, as many have implied," said Dr. Jerry Avorn, professor of Medicine at Harvard Medical School and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics Brigham and Women's Hospital.
"This shows that the problem isn't generic versus brand, but good manufacturing practices versus sloppy manufacturing practices," said Merrill Goozner, a freelance writer and independent consultant to consumer groups. "The FDA needs more money to police the entire drug manufacturing supply chain, brand name and generic, over-the-counter or prescription."
The company and the FDA issued the voluntary recall of certain over-the-counter (OTC) children's and infants' liquid products after consumer complaints of "tiny particles" in the medicines, as well as the possibility that some of the medications "may contain a higher concentration of active ingredient than is specified" and "others may contain inactive ingredients that may not meet internal testing requirements," according to a press release on the company's Web site.
The recall affects a total of 43 different products sold under the brand names of Tylenol, Motrin, Zyrtec and Benadryl.
Thus far, there is no indication as to which medications of those recalled are linked to each of the problems cited in the company's press release.
Elaine Gansz Bobo, a spokeswoman for the FDA, said that at this time, the agency believes the affected medications pose little threat.
"With some recalls, every bit of information is present before the recall," Bobo said. "But this product, because it is widely used and is used in a vulnerable population, it is better to get the information out there... This is not an imminent public health risk."
"The important thing for consumers to understand is that there are no adverse events related to it," said Bonnie Jacobs, spokeswoman for McNeil Consumer Healthcare.
Still, the recall is the drugmaker's third in a year due to quality problems. In December, certain arthritis medications and other products were pulled from the market after reports of an "unusual moldy, musty, or mildew-like odor" and cases of gastrointestinal illness linked to the consumption of these products.
Last September, a number of pediatric liquid products were recalled due to concerns over the quality of an inactive ingredient that is a component of these drugs.
"Speaking as a parent and a pharmacologist, the frequency of these recalls does not foster great confidence in the manufacturing standards for these medicines in that they are being released before quality testing is completed," said Dr. David Kroll, professor of Pharmaceutical Sciences at North Carolina Central University in Durham. "I was struck in particular by the comment from the FDA that parents consider substituting generic versions of the child medicines, rather than use adult strength medicines."
Another potential problem is that the recall affects the same category of medications that came under fire from an FDA advisory committee in 2007.